Highlights

  • Technegas uses an inhaled radiolabelled carbon aerosol to support lung ventilation imaging.
  • Cyclopharm reported 1H2026 revenue of $17.5m, an increase of approximately 14%.
  • US Technegas revenue increased 74% to $2.1m in the first half of 2026.
  • The company reported 70 revenue-generating US sites at 30 June and 83 by 12 August 2026.
  • Hospital adoption, recurring consumables and regulatory requirements remain key operating considerations.

Cyclopharm Limited (ASX:CYC) develops and commercialises Technegas, a nuclear medicine product used to image ventilation in the lungs, alongside a business distributing other nuclear medicine products. The technology produces an inhalable, radiolabelled carbon aerosol for ventilation scans. During 2026, its US deployment and hospital uptake have become central to the company’s commercial activities.

How Technegas Produces a Lung Ventilation Image

Technegas consists of ultra-fine carbon particles labelled with technetium-99m. After inhalation, the particles travel into the airways and lungs, allowing nuclear medicine cameras to map the distribution of inhaled gas. Clinicians can assess lung ventilation and compare it with blood-flow imaging when investigating conditions such as suspected pulmonary embolism. The technology supports diagnostic assessment; it does not itself treat a respiratory condition.

For Cyclopharm Limited (ASX:CYC), particle delivery is an important part of Technegas's practical role. The inhaled tracer produces a ventilation image reflecting where the particles travel. Image quality, patient technique and clinical interpretation remain relevant to its use.

First-Half Revenue and US Hospital Installations

Cyclopharm Limited (ASX:CYC) reported total revenue of $17.5m for the six months ended 30 June 2026, approximately 14% higher than in the comparable period. The company attributed increasing importance to its US business, where Technegas revenue rose 74% from $1.2m to $2.1m. The first-half gross margin reached 56.3%, compared with 53.5% in the corresponding period. These figures provide separate measures of overall activity, US sales and revenue mix.

At 30 June 2026, Cyclopharm had 70 revenue-generating US sites, compared with 35 one year earlier. The reported figure increased to 83 by 12 August 2026. Cyclopharm Limited (ASX:CYC) also identified an engaged US pipeline of 1,684 sites at that August date. A pipeline represents potential implementation activity rather than completed installations or guaranteed future sales, making the distinction between engaged and revenue-generating sites important.

Recurring Consumables and Broader Clinical Adoption

Technegas equipment placement creates opportunities for ongoing consumable sales when sites conduct patient procedures. Cyclopharm describes its commercial model as incorporating installation-related receipts, access fees and patient-linked consumables. The number of operational sites and frequency of clinical use therefore influence recurring receipts, while hospital procurement, staff training and implementation schedules influence the pace of deployment.

In July 2026, the company announced an 11-site Technegas rollout with University Hospitals and reported that updated US lung imaging guidelines described Technegas as generally preferred when available. Cyclopharm Limited (ASX:CYC) also announced a 2026 study involving Technegas and AI-driven lung analysis in chronic obstructive pulmonary disease. Such research reflects evaluation of additional uses and should not be interpreted as confirmation of a new approved indication.

Funding, Execution and Clinical Constraints

Cash at 30 June 2026 stood at $12.2m, according to the first-half results presentation. Cyclopharm also reported a net loss after tax of $8.8m for the half year. These figures illustrate the financial resources and expenditure associated with expanding commercial activity. Medical-device uptake can remain dependent on hospital purchasing decisions, reimbursement, installation capacity, clinical evidence and applicable regulatory requirements.

Key Insights

Cyclopharm Limited (ASX:CYC) combines an established lung ventilation imaging product with an expanding US commercial network. First-half 2026 revenue, hospital-site growth and recurring consumable arrangements help describe its current operating position. The distinction between installations, patient use and prospective hospital demand remains central to assessing reported progress, alongside expenditure and medical regulatory obligations.